FOXO1 and cancer: To evaluate the translational value of this triple combination therapy in an autoimmune model of diabetes, we used Repsox and the γ-secretase inhibitor PF-03084014, currently in phase II trials for the treatment of different forms of cancer (36), in combination with the chemical FOXO1 inhibitor FBT10 (Figure 6A) (20, 21).